Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients

Table 2 Baseline variables according to treatment response

Variable	All subjects		HCV genotype-1		HCV genotype-3
	R(n = 130)	NR(n = 22)	R(n = 77)	NR(n = 17)	R(n = 51)	NR(n = 5)
Age (yr)	40.9 ± 9.4a	47.7 ± 11.5	41.7 ± 9.0	47.9 ± 11.9	40.0 ± 10.1	46.8 ± 8.9
HCV RNA (× 105 IU/mL)	35.6 ± 55a	60.1 ± 99.5	37.9 ± 48.6	70.1 ± 111.6	32.4 ± 64.9	26.3 ± 16.8
Liver fibrosis stage	2.2 ± 1.5	3.0 ± 1.7	2.3 ± 1.5	3.0 ± 1.8	1.8 ± 1.3	3.0 ± 0.0
ALT (IU/L)	71.9 ± 57.7	100.9 ± 108.7	74.2 ± 63.9	77.9 ± 63.7	70.1 ± 47.9	198.7 ± 203.6
AST (IU/L)	44.5 ± 26.4	71.2 ± 66.8	44.9 ± 28.7	58.5 ± 47.6	44.4 ± 23.3	125.2 ± 113.5
BMI (kg/m2)	26.9 ± 4.0	25.8 ± 3.4	27.2 ± 3.5a	25.1 ± 3.0	26.2 ± 4.6	29.5 ± 3.7

Data are presented as mean ± SD;

^aP < 0.05 vs NR. ALT: Alanine transaminase; AST: Aspartate transaminase; BMI: Body mass index; HCV: Hepatitis C virus; NR: Non-responder; R: Responder (achieved sustained virologic response).